Kateryna Borodina/iStock via Getty Images
- Additional data from a phase 2 study of Zealand Pharma’s (ZLDPF) petrelintide indicated that the amylin analog led to significant weight loss over 42 weeks of treatment.
- Active-arm participants in the placebo-controlled ZUPREME-1 trial had mean reductions in weight from